Heart failure & cardiomyopathiesRandomised controlled trial
Catheter-Based Ablation to Improve Outcomes in Patients with Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction: Rationale and Design of the CABA-HFPEF-DZHK27 Trial
- Design paper of a randomised controlled trial
- investigator-initiated
- prospective
- open
- multicentre
- strategy trial
- blinded outcome assessment
- Safety outcome: complications of catheter ablation and death
All patients receive anticoagulation, rate control and heart failure (HF) management per current guidelines
Authors' conclusion
CABA-HFPEF-DZHK27 will define the role of systematic and early catheter ablation in patients with AF and HFpEF or HFmrEF.
Study context
- Population
- Patients with paroxysmal or persistent atrial fibrillation (AF) diagnosed within 24 months before enrolment and HFpEF or HFmrEFplanned (approximately)
- Participants
- 1,548 patients
- Comparison
- Early catheter ablation vs usual care
- Primary endpoint
- Composite of:
- CV death
- Stroke
- Total unplanned hospitalizations for HF or ACS
- Follow-up
- Until the end of the trial
Primary result
As reported in the abstract
- Powered for a rate ratio of 0.75 (two-sided alpha = 0.05, 1-beta = 0.8)
- design paper; no results reported
Original publication
Catheter-Based Ablation to Improve Outcomes in Patients with Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction: Rationale and Design of the CABA-HFPEF-DZHK27 Trial. Eur J Heart Fail. Published 18 July 2024. doi:10.1002/ejhf.3373
Summarised from the published abstract; every number is checked against it